{"id":"placebo-matching-pegcetacoplan","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4298211","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegcetacoplan is a pegylated aptamer that binds and inhibits complement component C3, preventing its cleavage and activation of the alternative complement pathway. By reducing complement-mediated inflammation and cell destruction, it aims to treat complement-driven diseases. As a placebo matching formulation, this control contains no active drug and is used for blinded comparison in clinical trials.","oneSentence":"This is a placebo control arm matching the active drug pegcetacoplan, which is a complement C3 inhibitor that blocks the alternative complement pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:53.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"C3 glomerulopathy"},{"name":"Post-transplant thrombotic microangiopathy"}]},"trialDetails":[{"nctId":"NCT05096403","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2022-10-20","conditions":"Cold Agglutinin Disease","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Pegcetacoplan","genericName":"Placebo matching Pegcetacoplan","companyName":"Swedish Orphan Biovitrum","companyId":"swedish-orphan-biovitrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm matching the active drug pegcetacoplan, which is a complement C3 inhibitor that blocks the alternative complement pathway. Used for Paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, Post-transplant thrombotic microangiopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}